Hence, small molecules targeting circadian clock regulators that may possess immune-modulatory properties in addition to pro-myogenic actions could be developed to promote regenerative capacity while alleviating chronic inflammation in DMD, which may yield robust efficacy in ameliorating muscular dystrophy. The gene discussed is CLOCK; the disease is muscular dystrophy.